Biopharma 2018: Is There Still A Place For Pharma In The New Health Care Economy?

2018 will be a time of transition in health care, when biopharma’s counterparts in adjacent industry segments scale up in a radical redesign of their traditional business models. Biopharma is not moving as quickly, and it confronts a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.

2018-Pharma_IV1801_web-1200.gif

The key challenge confronting biopharma in 2018 is the disconnect between an abundance of transformative science and a hidebound commercial and regulatory model that continues to place barriers to making the right medicines accessible to patients who need them. It’s a structural problem in the delivery and financing of health care overall, but one that impacts biopharma disproportionately by adding to the cost of drug development, denting the benefits of innovation and diminishing the industry’s reputation as a force for social good.

Solving for the imperfections that guide institutional behavior – can human health provision ever be anything but “messy”? – will...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.